A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression.
about
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatmentAssociation study of CREB1 with Major Depressive Disorder and related phenotypes.Reproductive aging, sex steroids, and mood disordersPharmacogenetics of antidepressant response.Effects of BDNF polymorphisms on antidepressant action.Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach.β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variantReview and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Pharmacogenetics of antidepressantsThe promise and reality of pharmacogenetics in psychiatryThe C825T Polymorphism of the G-Protein β3 Gene as a Risk Factor for Depression: A Meta-Analysis.The relationship between single nucleotide polymorphisms in 5-HT2A signal transduction-related genes and the response efficacy to selective serotonin reuptake inhibitor treatments in Chinese patients with major depressive disorderPharmacogenomics with antidepressants in the STAR*D study.Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics.Cognitive Functions across the GNB3 C825T Polymorphism in an Elderly Italian Population.SNPs in genes encoding G proteins in pharmacogenetics.Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis.BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients.Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Epistatic Interactions between CREB and CREM Variants in Affective Disorder.Variation in GNB3 predicts response and adverse reactions to antidepressants.Delivering a pharmacogenetic service: is there a role for genetic counselors?Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression.Val66Met BDNF genotypes in melancholic depression: effects on brain structure and treatment outcome.Imaging genetics: implications for research on variable antidepressant drug response.Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder.Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance.Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.Pharmacogenetic testing: not as simple as it seems
P2860
Q27015830-5CCDC91F-2A41-4C6B-B1AA-12AC479C948CQ33750920-AFB1493E-A687-484C-85F5-22B21A20F56DQ33820067-736DC961-6812-422D-AFC8-E6835D923557Q34155796-C3C47F18-E277-4C7F-A252-912B94BF9AE6Q34497530-11D7E830-A4E2-49C4-9F74-3CDEDE31F85AQ34764142-ED455DD9-21FC-478E-9759-705A4FC6C74FQ34779277-C31728E0-5C67-4206-8326-8855326CE188Q34871885-0D4B0027-8F7F-47AF-B099-17262ADA42F2Q35026088-553443E5-71D1-4368-A690-00145612AC37Q35226451-D6E8A87A-B28F-4D88-857D-B767B018D60DQ35683649-26EC2297-BECA-474F-BBC3-0798A29BD6A1Q36092745-144F236E-C943-402F-9108-658E431D587FQ37205961-7D564C3E-43FD-436E-8303-9A699ECD3FECQ37264563-44E5F3A8-551B-4601-A29B-C412705CED64Q37285891-440771FC-4EA9-43CF-8C57-401E25CBE176Q37880876-27A51D1F-1A40-476F-862A-8C4B2A7A40E1Q37989490-FCB8294A-B62B-4242-8D15-D53FC9488C23Q38121519-BAB99492-B9CD-4FEE-BCDA-8AF761A45579Q38251192-4500A814-2D20-42AA-984A-32074FA1F549Q38540142-33DA448E-82A6-4B31-845F-9537AB6B74F8Q38823641-9877026D-02E3-4E90-9A13-73EC72312FCCQ38983579-B80A7F18-6ACE-4F2E-BDAA-1D0F08C15897Q39667520-F0B6979E-0E2E-42DF-ABBE-AF3AA0A3B51EQ45147314-B9F4741C-A560-4A1B-B52C-598B8CAE3495Q45421313-89D2A7AB-5A0D-4950-B284-A20C74F036F4Q46114404-AE07F188-13F3-4142-9151-E9AC3F8B23D0Q46654662-98828595-D790-4045-BA0B-2E688EE5C9CCQ48148747-37134146-41C6-4AC6-89A9-00DBA98F35F3Q48267690-E9E6B2AC-13BF-4858-AA1B-3EA1FDF1FBCDQ48315286-74160435-2D63-4EAA-9B97-2F2761B2DD83Q48765517-D809D51B-3F4A-42C0-87CC-D4D3634BD213Q56784514-141B4D86-259F-4545-B7CC-560591B048BC
P2860
A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A splice site polymorphism in ...... essant efficacy in depression.
@en
A splice site polymorphism in ...... essant efficacy in depression.
@nl
type
label
A splice site polymorphism in ...... essant efficacy in depression.
@en
A splice site polymorphism in ...... essant efficacy in depression.
@nl
prefLabel
A splice site polymorphism in ...... essant efficacy in depression.
@en
A splice site polymorphism in ...... essant efficacy in depression.
@nl
P2093
P50
P1476
A splice site polymorphism in ...... essant efficacy in depression.
@en
P2093
Douglas Blackwood
Ian C Reid
Murray J V Wilkie
Richard K Day
P304
P356
10.1097/FPC.0B013E32801A3BE6
P577
2007-03-01T00:00:00Z